 Experimental autoimmune encephalomyelitis alpha soluble receptor role development experimental autoimmune encephalomyelitis EAE effects vivo treatment alpha antagonist clinical course EAE First Lewis rats guinea pig myelin CFA consecutive days i.p injections recombinant human alpha Clinical signs paralysis alpha-treated groups duration severity injected controls addition weight loss alpha-treated groups controls enhanced weight loss due alpha injections CFA-treated rats alpha weight injected CFA-treated controls Second soluble mouse alpha beta antagonist Treatment guinea pig myelin/CFA rats consecutive days onset EAE severity paralysis weight loss duration disease Treatment effective EAE consecutive days immunization treatment regimens days days days immunization effective EAE data inflammation central nervous system addition biological activity vivo soluble receptors beneficial treatment autoimmune inflammatory diseases